Cheng You, He Yingnan, Gopinath Karthik, Billot Benjamin, Iglesias Juan Eugenio, Wu Chao-Yi, Dodge Hiroko, Wills Anne-Marie, Carlyle Becky, Kivisäkk Pia, Hyman Bradley T, Arnold Steven E, Das Sudeshna
Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.
Brain Commun. 2025 May 30;7(3):fcaf210. doi: 10.1093/braincomms/fcaf210. eCollection 2025.
The relationship between cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease and neurodegenerative effects is not fully understood. This study investigates neurodegeneration patterns across CSF Alzheimer's disease biomarker groups, the association of brain volumes with CSF amyloid and tau status and sex differences in these relationships in a clinical neurology sample. MRI and CSF Alzheimer's disease biomarkers data were analysed in 306 patients of the Mass General Brigham healthcare system aged 50+ (mean age = 68.4 ± 8.8 years; 43.1% female), who had lumbar punctures within 1 year of clinical MRI scans. We first analysed neurodegeneration patterns across four biomarker groups: 60 controls (A-T-&CU; amyloid negative, tau negative, cognitively unimpaired), 25 A+T- (amyloid positive, tau negative), 121 A+T+ (amyloid positive, tau positive) and 100 other dementia (A-T-&CI; amyloid negative, tau negative, cognitively impaired). Second, we examined volumetric associations with amyloid (amyloid positive, tau negative versus control) and tau in the presence of amyloid (amyloid positive, tau positive versus amyloid positive, tau negative) across 52 brain areas. Third, we examined sex differences in these relationships. Finally, we validated core analyses across three independent datasets-NACC (National Alzheimer's Coordinating Center), ADNI (Alzheimer's Disease Neuroimaging Initiative) and EPAD (European Prevention of Alzheimer's Dementia)-totalling 3137 participants, and performed meta-analyses to obtain more robust estimates. We observed distinct neurodegeneration patterns across biomarker groups, with disrupted connectivity (brain volume covariance networks) in amyloid positive and other dementia groups, while amyloid and tau negative, cognitively unimpaired controls exhibited the most connected network. Amyloid was associated with subcortical, cerebellar and brainstem atrophy, with consistent association observations in the thalamus and amygdala across all four datasets. Tau in the presence of amyloid demonstrated general brain shrinkage through enlargement of extracerebral CSF, alongside unexpected ventricle shrinkages. Sex-based analyses revealed that A+T+ (amyloid positive, tau positive) had lower sex differences in connectivity patterns compared with other groups. Sex differences were also noted in amyloid-related ventricular volume changes. This study reveals how amyloid and tau affect brain connectivity and volume across sex and CSF biomarker groups, emphasizing global brain changes and sex differences. By leveraging automated pipelines and advanced MRI and biomarker analyses, we extracted meaningful and replicable findings from heterogeneous clinical samples from real-world data. The meta-analyses across four datasets enhance the generalizability of our results.
阿尔茨海默病脑脊液(CSF)生物标志物与神经退行性变效应之间的关系尚未完全明确。本研究在一个临床神经学样本中,调查了不同CSF阿尔茨海默病生物标志物组的神经退行性变模式、脑容量与CSF淀粉样蛋白和tau蛋白状态的关联以及这些关系中的性别差异。对麻省总医院布莱根医疗系统中306名年龄在50岁以上(平均年龄 = 68.4 ± 8.8岁;43.1%为女性)的患者进行了MRI和CSF阿尔茨海默病生物标志物数据的分析,这些患者在临床MRI扫描后1年内接受了腰椎穿刺。我们首先分析了四个生物标志物组的神经退行性变模式:60名对照者(A-T-&CU;淀粉样蛋白阴性、tau蛋白阴性、认知未受损)、25名A+T-(淀粉样蛋白阳性、tau蛋白阴性)、121名A+T+(淀粉样蛋白阳性、tau蛋白阳性)和100名其他痴呆患者(A-T-&CI;淀粉样蛋白阴性、tau蛋白阴性、认知受损)。其次,我们在52个脑区检查了淀粉样蛋白(淀粉样蛋白阳性、tau蛋白阴性与对照)以及存在淀粉样蛋白时tau蛋白(淀粉样蛋白阳性、tau蛋白阳性与淀粉样蛋白阳性、tau蛋白阴性)与脑容量的关联。第三,我们研究了这些关系中的性别差异。最后,我们在三个独立数据集——NACC(国家阿尔茨海默病协调中心)、ADNI(阿尔茨海默病神经影像学倡议)和EPAD(欧洲预防阿尔茨海默病痴呆症)——中对核心分析进行了验证,这三个数据集共有3137名参与者,并进行了荟萃分析以获得更可靠的估计。我们观察到不同生物标志物组存在明显的神经退行性变模式,淀粉样蛋白阳性组和其他痴呆组的连接性(脑容量协方差网络)受到破坏,而淀粉样蛋白和tau蛋白均为阴性、认知未受损的对照组表现出连接性最强的网络。淀粉样蛋白与皮质下、小脑和脑干萎缩相关,在所有四个数据集中丘脑和杏仁核均观察到一致的关联。存在淀粉样蛋白时,tau蛋白通过脑外CSF扩大导致全脑萎缩,同时脑室出现意外缩小。基于性别的分析显示,与其他组相比,A+T+(淀粉样蛋白阳性、tau蛋白阳性)在连接模式上的性别差异较小。在淀粉样蛋白相关的脑室容积变化中也注意到了性别差异。本研究揭示了淀粉样蛋白和tau蛋白如何影响不同性别和CSF生物标志物组的脑连接性和脑容量,强调了全脑变化和性别差异。通过利用自动化流程以及先进的MRI和生物标志物分析技术,我们从真实世界数据的异质性临床样本中提取了有意义且可重复的发现。对四个数据集进行的荟萃分析提高了我们结果的普遍性。